Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRL 201805

Next Previous
Drug Profile

IRL 201805

Alternative Names: '1805; IRL-201805

Latest Information Update: 25 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kings College London; Peptinnovate
  • Developer Revolo Biotherapeutics
  • Class Anti-inflammatories; Antirheumatics; Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 25 Jul 2024 Revolo Biotherapeutics plans a phase IIa trial for Ulcerative colitis (unspecified) in 2025 (Revolo Biotherapeutics pipeline, July 2024)
  • 09 Oct 2023 Revolo Biotherapeutics plans a phase IIa trial for Rheumatoid arthritis (unspecified) in H1 of 2024 (Revolo Biotherapeutics pipeline, October 2023)
  • 12 Jun 2023 Pharmacodynamics data from a clinical study in rheumatoid arthritis released by Revolo Biotherapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top